Sanofi can confirm that Clexane® is in stock in the UK across all doses and we are confident in our ability to supply in response to anticipated demand throughout 2020.
In the best interest of patients and healthcare professionals, we are committed to continuing to respond to market demand.
As such, we hold supply of Clexane® above the minimum expectation set by the Department of Health and Social Care (DHSC).
If a local agent is low in stock, Clexane® can be transferred from another agent holding stock.
LMWHs are complex biological products, produced from porcine intestinal mucose, which require a high standard of manufacturing quality and traceability processes to address health authorities’ standards.
An increasing number of supply shortages from all different suppliers of LMWHs has been observed in the last two years. [i] This has been largely driven by the multifaceted and interconnected network which makes access to LMWHs possible.
Added to this, over the past decade (from 2008 to 2018), the clinical use of LMWHs has nearly doubled. [ii] Global demand for LMWHs is expected to continue to grow in a similar manner to address medical need.
Sanofi has responded by taking measures to improve continuity of supply in the UK through a dedicated packaging production line in Europe, additional warehouse capacity to support stockpiling of products, and a capability to adapt production across three European manufacturing sites.
As a leading LMWH manufacturer, we also remain engaged in dialogue with health authorities in all European countries to explore additional measures required to support sustainable patient access to LMWHs.
The new Clexane® (enoxaparin) Dividella packaging is only available in the UK and Ireland. This helps us to secure volume of Clexane dosages exclusively for these two countries.
The new Clexane® compact packs are smaller than the older packaging, providing a reduction in occupied space.
The simplification of the production line and reduction of steps needed for the compact packs is expected to improve the long-term continuity of the supply of the product for the UK.
The transition to the new packaging is in response to feedback from healthcare professionals and may improve the continuity of supply to the UK.
[i] Source: Extract from the notification from the drug shortages websites of each country